Previous clinical trials have established that dual HER2‐targeted blockade with trastuzumab and pertuzumab (or lapatinib) can provide synergistic benefits for patients with HER2‐positive breast cancer.13, 28, 29, 30. Here, ERBB2 is linked to breast carcinoma.